Biotie's Financial Statement Report and Corporate Governance Statement 2015 published

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE   March 22, 2016 at 10 a.m.

Biotie's Financial Statement Report and Corporate Governance Statement 2015 published

Biotie Therapies Corp.'s (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") Financial Statement Report for the financial period ended 31 December 2015 and Corporate Governance Statement 2015 have been published.

The documents are attached in pdf format to this release. Both documents are also available on the Company's website www.biotie.com in English and Finnish language.

In addition, Biotie expects to file its 2015 annual report on Form 20-F with the U.S. Securities and Exchange Commission (the "SEC") later today. The Form 20-F will be available on Biotie's website after it is filed with the SEC.

Turku, March 22, 2016

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
Nasdaq Helsinki Ltd
Main Media
www.biotie.com 

About Biotie

Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver.

Biotie's shares are listed on NASDAQ Helsinki (BTH1V) and ADS on Nasdaq Stock Market LLC (BITI).